Similar articles

• An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.

  Liebow A, Li X, Racie T, Hettinger J, Bettencourt BR, Najafian N, Haslett P, Fitzgerald K, Holmes RP, Erbe D, Querbes W, Knight J. Liebow A, et al. J Am Soc Nephrol. 2017 Feb;28(2):494-503. doi: 10.1681/ASN.2016030338. Epub 2016 Jul 18. J Am Soc Nephrol. 2017. PMID: 27432743 Free PMC article.
• Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.

  Li X, Knight J, Fargue S, Buchalski B, Guan Z, Inscho EW, Liebow A, Fitzgerald K, Querbes W, Todd Lowther W, Holmes RP. Li X, et al. Biochim Biophys Acta. 2016 Feb;1862(2):233-9. doi: 10.1016/j.bbadis.2015.12.001. Epub 2015 Dec 2. Biochim Biophys Acta. 2016. PMID: 26655602 Free PMC article.
• Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.

  Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators. Garrelfs SF, et al. N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712. N Engl J Med. 2021. PMID: 33789010 Clinical Trial.
• Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria.

  Forbes TA, Brown BD, Lai C. Forbes TA, et al. Br J Clin Pharmacol. 2022 Jun;88(6):2525-2538. doi: 10.1111/bcp.14925. Epub 2021 Jun 11. Br J Clin Pharmacol. 2022. PMID: 34022071 Free PMC article. Review.
• Lumasiran: First Approval.

  Scott LJ, Keam SJ. Scott LJ, et al. Drugs. 2021 Feb;81(2):277-282. doi: 10.1007/s40265-020-01463-0. Drugs. 2021. PMID: 33405070 Review.